Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

NCT07070713 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER_GOV

Sponsor class

Conditions

Metastatic Colorectal Cancer With Left-sided Primary Tumor
Immunotherapy

Interventions

DRUG: FOLFOXIRI + QL1706 + Bevacizumab
DRUG: FOLFOX+QL1706+Cetuximab

Sponsor

Fujian Cancer Hospital